Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HUTCHMED (China) Limited (HCM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. HUTCHMED files annual reports on Form 20-F and submits current information on Form 6-K under the Securities Exchange Act of 1934. These filings often attach press releases and announcements that detail clinical, regulatory and corporate developments.
For a biopharmaceutical company focused on targeted therapies and immunotherapies, Form 6-K reports can be particularly important. Recent 6-Ks have included exhibits relating to Phase III clinical trial readouts such as the SACHI study of savolitinib plus TAGRISSO® in EGFR-mutated non-small cell lung cancer, initiation of global clinical development for the ATTC candidate HMPL-A251, and NDA acceptances with priority review for fanregratinib in intrahepatic cholangiocarcinoma and savolitinib in MET-amplified gastric cancer. Other 6-Ks have covered R&D update events, clinical data presentations at major congresses, and corporate governance matters.
Investors can use these filings to track pipeline progress, regulatory interactions and capital market disclosures. While the 6-Ks referenced here focus on attaching press releases, HUTCHMED’s broader SEC reporting framework also includes its Form 20-F annual report, which typically provides more comprehensive information on risk factors, research and development activities, and financial statements.
On Stock Titan, HCM filings are updated as new documents are released to EDGAR, and AI-powered tools summarize key points to make lengthy disclosures more accessible. Users can quickly see which filings relate to clinical milestones, such as completion of enrollment in the SAFFRON Phase III trial of ORPATHYS® and TAGRISSO®, or to business topics like board appointments and voting rights announcements. This page is a useful starting point for anyone analyzing how HUTCHMED’s oncology and immunology strategy is reflected in its official SEC communications.
HUTCHMED (China) Limited reports that the Phase III registration part of its ESLIM-02 trial of sovleplenib in adults with warm antibody autoimmune hemolytic anemia (wAIHA) in China met its primary endpoint. The study achieved a durable hemoglobin response rate between weeks 5 and 24, indicating rapid and sustained improvements in red blood cell levels for relapsed or refractory patients.
Earlier Phase II data showed hemoglobin benefits versus placebo with overall response rates of 43.8% vs 0% in the first 8 weeks, and 66.7% over 24 weeks of sovleplenib treatment with a favorable safety profile. HUTCHMED plans to submit a New Drug Application for sovleplenib in wAIHA to China’s NMPA in the first half of 2026 and is also developing the drug for immune thrombocytopenia, where a China Phase III trial has already reported positive results.
HUTCHMED (CHINA) LIMITED filed a Form 6-K furnishing Exhibit 99.1, a press release about completion of enrollment in the SAFFRON global phase III trial evaluating the combination of ORPATHYS and TAGRISSO for certain lung cancer patients with MET overexpression and/or amplification after progression on TAGRISSO.
FAQ
What is the current stock price of Hutchmed (China) (HCM)?
What is the market cap of Hutchmed (China) (HCM)?
